(19)
(11) EP 1 054 687 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.07.2008 Bulletin 2008/29

(45) Mention of the grant of the patent:
21.05.2008 Bulletin 2008/21

(21) Application number: 98966053.5

(22) Date of filing: 23.12.1998
(51) International Patent Classification (IPC): 
A61K 38/19(2006.01)
C12N 15/85(2006.01)
C12N 15/11(2006.01)
 A61K 39/395(2006.01)
C12N 5/16(2006.01)
G01N 33/574(2006.01)
(86) International application number:
PCT/US1998/027373
(87) International publication number:
WO 1999/033485 (08.07.1999 Gazette 1999/27)

(54)

EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS

EXPRESSIONSVEKTOREN UND ZELLINIEN ZUR EXPRESSION VON VASKULÄREM WACHSTUMSFAKTOR D, SOWIE VERFAHREN ZUR BEHANDLUNG VON MELANOMEN

VECTEURS D'EXPRESSION ET LIGNEES CELLULAIRES EXPRIMANT LE FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE D, ET PROCEDE DE TRAITEMENT DES MELANOMES

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 24.12.1997 AU PP113197
29.05.1998 US 87392 P

(43) Date of publication of application:
29.11.2000 Bulletin 2000/48

(73) Proprietor: Vegenics Limited
Toorak, Victoria 3142 (AU)

(72) Inventors:
  • ACHEN, Marc, G.
    North Melbourne, VIC 3051 (AU)
  • STACKER, Steven, Alan
    North Fizroy, VIC 3068 (AU)
  • ALITALO, Kari
    FIN-02100 Espoo (FI)

(74) Representative: Goodfellow, Hugh Robin et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA
London WC1A 2RA (GB)


(56) References cited: : 
EP-A- 0 935 001
WO-A-98/07832
 WO-A-95/24473
WO-A-98/24811
   
  • YAMADA et al, "Molecular Cloning of a Novel Vascular Endothelial Growth Factor, VEGF-D", GENOMICS, 1997, Vol. 42, pages 483-488. XP002918205
  • ORLANDINI et al, "Identification of a C-fos-Induced Gene that is Related to the Platelet-Derived Growth Factor/Vascular Endothelial Growth Factor Family", PROC. NATL. ACAD. SCI. USA, October 1996, Vol. 93, pages 11675-11680. XP002918340
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).